PT  - JOURNAL ARTICLE
AU  - Hiroshi Tsuda
AU  - Kiyoshi Ito
AU  - Nobuo Yaegashi
AU  - Akira Hirasawa
AU  - Tamotsu Sudo
AU  - Tsunekazu Kita
AU  - Yoshito Terai
AU  - Junzo Kigawa
AU  - Toru Sugiyama
AU  - Daisuke Aoki
TI  - Relationship Between ABCF2 Expression and Response to Chemotherapy or Prognosis in Clear Cell Adenocarcinoma of the Ovary
AID  - 10.1111/IGC.0b013e3181a835fc
DP  - 2010 Jun 01
TA  - International Journal of Gynecologic Cancer
PG  - 794--797
VI  - 20
IP  - 5
4099  - http://ijgc.bmj.com/content/20/5/794.short
4100  - http://ijgc.bmj.com/content/20/5/794.full
SO  - Int J Gynecol Cancer2010 Jun 01; 20
AB  - Objectives: The purpose of this study was to evaluate the association of ABCF2 (adenosine triphosphate-binding cassette superfamily F2) protein expression with response to chemotherapy and prognosis in patients with clear cell adenocarcinoma (CCC) of the ovary.Methods: One hundred sixty-five patients with CCC were studied, and cytoplasmic ABCF2 expression was detected by immunohistochemical staining. All patients underwent platinum-based primary chemotherapy followed by primary surgery.Results: Adenosine triphosphate-binding cassette superfamily F2 expression was detected in 118 (71.5%) of 165 patients and was not related to age or clinical stage. The response rate to chemotherapy in 38 patients with measurable disease was 47.3% (18/38). The response rate tended to be higher in patients without ABCF2 expression than in those with ABCF2 expression; however, this difference was not significant (66.7% vs 34.8%, P = 0.096). There was no significant difference in overall survival between ABCF2-positive and ABCF2-negative cases (median survival time, 1175 vs 1257 days; P = 0.24).Conclusions: Adenosine triphosphate-binding cassette superfamily F2 protein was highly expressed in CCC of the ovary, but expression was not related to age, clinical stage, chemoresponse, or prognosis.